A Dose Ranging Study To Investigate The Efficacy And Safety Of SB-742457 In Alzheimer's Disease

GlaxoSmithKline (GSK)

Status and phase

Completed

Phase 2

Conditions

Alzheimer's Disease

Treatments

Drug: SB-742457

Study type

Interventional

Funder types

Industry

Identifiers

NCT00224497

AZ3100603

Details and patient eligibility

About

The purpose of this study is to find out if SB-742457 is a safe treatment and what effects it has on the symptoms of mild to moderate Alzheimer's disease. SB-742457 is a new treatment which is thought to increase the levels of certain chemicals in the brain that are often decreased in patients with Alzheimer's disease.

Sex

All

Ages

50 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Clinical diagnosis of probable mild-to-moderate Alzheimer's disease as determined by the NINCDS-ADRDA and DSM-IV criteria with an MMSE score of 12-24.
Subjects and their caregivers must provide informed consent prior to study entry.
Adequate blood pressure and laboratory values.

Exclusion criteria

Females of child-bearing potential.
Have other causes of dementia such as vascular damage, depression, bipolar affective disorder, schizophrenia, syphilis, vitamin B12 deficiency or thyroid deficiency.
Subjects taking medication for Alzheimer's disease or centrally acting agents which might impact study outcomes.
Subjects taking agents for which there is a theoretical risk of interaction with SB-742457.
Subjects with known hypersensitivity to sunlight or seizures.